Chimeric antigen receptor T cells in the fast lane among autoimmune disease therapies

Chimeric antigen receptor T cells in the fast lane among autoimmune disease therapies

In this commentary, we highlight recent studies demonstrating the feasibility and promise of chimeric antigen receptor (CAR) T‐cell therapy in treating a number of autoimmune disorders including systemic lupus erythematosus and compare CAR T cells to other therapies aimed at depleting B‐lineage cell...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical & Translational Immunology 2024, Vol.13 (4), p.e1502-n/a
Hauptverfasser: Ding, Zhoujie, Tarlinton, David
Format: Artikel
Sprache:eng
Schlagworte:
Antigens
Autoimmune diseases
B cells
Belimumab
Bone marrow
Chimeric antigen receptors
Disease
Diseases
Drug approval
FDA approval
Kinases
Ligands
Lupus
Lymphocytes
Lymphocytes T
Patients
Proteins
Remission (Medicine)
Systemic lupus erythematosus
T cells
Vaccines
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In this commentary, we highlight recent studies demonstrating the feasibility and promise of chimeric antigen receptor (CAR) T‐cell therapy in treating a number of autoimmune disorders including systemic lupus erythematosus and compare CAR T cells to other therapies aimed at depleting B‐lineage cells in treating such diseases.
ISSN:2050-0068
2050-0068
DOI:10.1002/cti2.1502